Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs rituximab with chemotherapy in newly diagnosed CD20-positive ALL
2024-517389-40-00Phase 2Completed
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute lymphoblastic leukemia (ALL) comparing Obinutuzumab + chemotherapy with Rituximab + chemotherapy (2 arms). Started Oct 2024; status: completed.
02
Drugs
obinutuzumabrituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-517389-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517389-40-00.